Continuing warfarin for 18 months after unprovoked PE reduces risk of recurrent VTE
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "Continuing Warfarin for 18 Months After Unprovoked PE Reduces Risk of Recurrent VTE." EE+ POEM Archive, John Wiley & Sons, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/428409/all/Continuing_warfarin_for_18_months_after_unprovoked_PE_reduces_risk_of_recurrent_VTE.
Continuing warfarin for 18 months after unprovoked PE reduces risk of recurrent VTE. In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2019. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/428409/all/Continuing_warfarin_for_18_months_after_unprovoked_PE_reduces_risk_of_recurrent_VTE. Accessed October 13, 2024.
Continuing warfarin for 18 months after unprovoked PE reduces risk of recurrent VTE. (2019). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/428409/all/Continuing_warfarin_for_18_months_after_unprovoked_PE_reduces_risk_of_recurrent_VTE
Continuing Warfarin for 18 Months After Unprovoked PE Reduces Risk of Recurrent VTE [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2019. [cited 2024 October 13]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/428409/all/Continuing_warfarin_for_18_months_after_unprovoked_PE_reduces_risk_of_recurrent_VTE.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Continuing warfarin for 18 months after unprovoked PE reduces risk of recurrent VTE
ID - 428409
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/428409/all/Continuing_warfarin_for_18_months_after_unprovoked_PE_reduces_risk_of_recurrent_VTE
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -